Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fingolimod, a S1P receptor modulator, exerts its beneficial effects in MS through its anti-inflammatory and anti-neurodegenerative effects.
|
31757428 |
2020 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulated evidence has shown the protective effects of S1P receptor modulators on MS and its animal model, experimental autoimmune encephalomyelitis (EAE).
|
31722234 |
2020 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Siponimod was recently approved by United States Federal Drug Administration for relapsing MS and active secondary progressive MS. Other S1P receptor modulators are being studied in phase 3 trials for relapsing MS. Cladribine received FDA approval as treatment for relapsing and active secondary progressive MS. Autologous hematopoetic stem-cell transplantation may be an option for treatment-refractory MS.
|
30985372 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multiple sclerosis drug Fingolimod (FTY720) is a potent S1P receptor agonist that causes peripheral lymphopenia.
|
31742704 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 is a sphingosine 1 phosphate (S1P) receptor agonist approved for the treatment of multiple sclerosis, which is a chronic inflammatory autoimmune disorder.
|
30300318 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 (Fingolimod) is a known sphingosine-1-phosphate (S1P) receptor agonist that exerts strong anti-inflammatory effects and was approved as the first oral drug for the treatment of multiple sclerosis by the US food and drug administration (FDA) in 2010.
|
31785606 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the neuroprotective potential of an S1P receptors (S1PR) modulator, fingolimod (FTY720), in multiple sclerosis (MS) and numerous other diseases has been observed over the past decade.
|
30138818 |
2018 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fingolimod hydrochloride (FTY720) is a first-in-class of sphingosine-1-phosphate (S1P) receptor modulator approved to treat multiple sclerosis by its phosphorylated form (FTY720-P).
|
29785244 |
2018 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data may be valuable for comparing the effects of novel S1P receptor modulating agents, which may be a therapeutic option for patients with secondary progressive MS as well.
|
29314605 |
2018 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we set out to determine whether FTY720, a molecule that binds sphingosine-1-phosphate (S1P) receptors and with known immunosuppressant effects mediating its therapeutic action in multiple sclerosis (MS), might modulate the impact of infection in a mouse model of AD.
|
28620801 |
2017 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting S1P receptors for inflammatory conditions has been successful in clinical trials leading to approval of the non-selective S1P modulator, fingolimod, for relapsing forms of multiple sclerosis.
|
28279838 |
2017 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fingolimod, is a recognized modulator of S1P receptors, and is the first orally active disease-modifying therapy that has been approved for the treatment of multiple sclerosis.
|
27823573 |
2017 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to fingolimod (ie, precursor of the S1P modulators commercially available for the treatment of relapsing-remitting [RR] multiple sclerosis [MS]), siponimod exhibits selective affinity for types 1 and 5 S1P receptor, leading to a lower risk of adverse events that are mainly induced by S1P3 receptor activation, such as bradycardia and vasoconstriction.
|
29138536 |
2017 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we will review how S1P receptor may be a promising therapeutic target for SP-MS and other autoimmune diseases such as psoriasis, polymyositis and lupus.
|
27890706 |
2017 |
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show involvement of Cd38, Cxcr4 and Akt and confirm these findings by the use of Cd38-knockout (B6.129P2-Cd38<sup>tm1Lnd</sup>/J) mice, S1P-receptor modulation during EAE and quantitative expression analysis in individuals with MS.
|
27519689 |
2016 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus S1P receptor signaling regulates human B-cell circulation and might be a factor contributing to the pathology of MS, chronic lymphocytic leukemia, and primary immunodeficiencies.
|
24679343 |
2014 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fingolimod-an S1PR modulator approved for the treatment of relapsing MS in some countries-is thought to act by downmodulating lymphatic S1P subtype 1 receptors.
|
21339486 |
2011 |
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrate that reactive astrocytes in MS lesions and cultured under proinflammatory conditions strongly enhance expression of S1P receptors 1 and 3.
|
20648639 |
2010 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 (fingolimod) is a first-in-class sphingosine 1-phosphate (S1P) receptor modulator that was highly effective in Phase II clinical trials for Multiple Sclerosis (MS).
|
19814729 |
2009 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review provides an overview on S1P activities and S1P receptor function in health and disease, and summarizes the clinical experience with FTY720 in transplantation and multiple sclerosis.
|
17561264 |
2007 |